NCT02521844 2024-10-08A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid TumoursEDDC (Experimental Drug Development Centre), A*STAR Research EntitiesPhase 1 Active not recruiting89 enrolled